MapLight Therapeutics, Inc. Common Stock
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irrit… Read more
MapLight Therapeutics, Inc. Common Stock (MPLT) - Net Assets
Latest net assets as of September 2025: $233.52 Million USD
Based on the latest financial reports, MapLight Therapeutics, Inc. Common Stock (MPLT) has net assets worth $233.52 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($257.22 Million) and total liabilities ($23.70 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $233.52 Million |
| % of Total Assets | 90.78% |
| Annual Growth Rate | 134.8% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 89.97 |
MapLight Therapeutics, Inc. Common Stock - Net Assets Trend (2022–2024)
This chart illustrates how MapLight Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MapLight Therapeutics, Inc. Common Stock (2022–2024)
The table below shows the annual net assets of MapLight Therapeutics, Inc. Common Stock from 2022 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $115.19 Million | +61.60% |
| 2023-12-31 | $71.28 Million | +241.55% |
| 2022-12-31 | $20.87 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to MapLight Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13328900100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $163.00K | 0.14% |
| Other Components | $314.40 Million | 272.93% |
| Total Equity | $115.19 Million | 100.00% |
MapLight Therapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of MapLight Therapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Foran Mining Corporation
OTCQX:FMCXF
|
$898.13 Million |
|
Eastcompeace Technology Co Ltd
SHE:002017
|
$898.39 Million |
|
Alliance Material Co., Ltd.
TWO:3595
|
$898.72 Million |
|
Northern Data AG
PINK:NDTAF
|
$898.75 Million |
|
Bonesupport Holding AB
ST:BONEX
|
$897.79 Million |
|
Wonik Holdings Co. Ltd
KQ:030530
|
$897.68 Million |
|
REPT BATTERO Energy Co., Ltd.
F:L52
|
$897.30 Million |
|
Yuanbao Inc. American Depositary Shares
NASDAQ:YB
|
$897.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MapLight Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 71,282,000 to 115,195,000, a change of 43,913,000 (61.6%).
- Net loss of 77,580,000 reduced equity.
- Other comprehensive income increased equity by 163,000.
- Other factors increased equity by 121,330,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-77.58 Million | -67.35% |
| Other Comprehensive Income | $163.00K | +0.14% |
| Other Changes | $121.33 Million | +105.33% |
| Total Change | $- | 61.60% |
Book Value vs Market Value Analysis
This analysis compares MapLight Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.43x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 35.47x to 6.43x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $0.50 | $17.87 | x |
| 2023-12-31 | $1.72 | $17.87 | x |
| 2024-12-31 | $2.78 | $17.87 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently MapLight Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -67.35%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.19x
- Recent ROE (-67.35%) is above the historical average (-96.44%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -143.82% | 0.00% | 0.00x | 1.89x | $-32.10 Million |
| 2023 | -78.15% | 0.00% | 0.00x | 1.28x | $-62.84 Million |
| 2024 | -67.35% | 0.00% | 0.00x | 1.19x | $-89.10 Million |
Industry Comparison
This section compares MapLight Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MapLight Therapeutics, Inc. Common Stock (MPLT) | $233.52 Million | -143.82% | 0.10x | $897.93 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |